Vanda Pharmaceuticals | VNDA - Current Assets


Vanda Pharmaceuticals reported $347.26M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.06B 14.31M Dec/2025
Agios Pharmaceuticals USD 942.05M 91.06M Dec/2025
Akebia Therapeutics USD 252.96M 5.38M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Anika Therapeutics USD 101.59M 2.27M Sep/2025
Arrowhead Research USD 1.17B 223.75M Dec/2025
AstraZeneca USD 28.72B 1.22B Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Esperion Therapeutics USD 360.46M 17.87M Sep/2025
Halozyme Therapeutics USD 825.21M 503.54M Dec/2025
Heron Therapeutics USD 229.4M 18.48M Sep/2025
Insmed USD 1.79B 137.6M Dec/2025
J&J USD 55.62B 1.01B Dec/2025
Lexicon Pharmaceuticals USD 145.08M 100.72M Jun/2025
Ligand Pharmaceuticals USD 832.27M 78.35M Dec/2025
Merck USD 47.56B 10.49B Sep/2025
Minerva Neurosciences USD 13.02M 2.53M Sep/2025
Moderna USD 6.54B 54M Dec/2025
Novartis USD 28.2B 2.26B Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Puma Biotechnology USD 143.58M 7M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 30.95B 3.09B Dec/2025
Takeda JPY 3.12T 195.82B Dec/2025
Teva Pharmaceutical Industries USD 13.95B 1.21B Dec/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025
Veracyte USD 488.38M 39.15M Dec/2025